No data to show
XNAS
CMND
Market cap4mUSD
Jun 23, Last price
0.89USD
1D
0.39%
1Q
-17.59%
IPO
-99.50%
Name
Clearmind Medicine Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
221.94%
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L-56.05%
CFO
-5m
Profile
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑10 | 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 4,666 | 8,798 | 8,533 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (4,666) | (8,798) | (8,533) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 378 | 24 | 41 | |||||
Tax Rate | ||||||||
NOPAT | (5,044) | (8,822) | (8,573) | |||||
Net income | (5,255) -56.05% | (11,955) 27.04% | (9,411) 128.27% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 2,192 | 8,037 | 795 | |||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 37 | 52 | ||||||
Long-term debt | 70 | 52 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 1,959 | |||||||
Net debt | (6,757) | (4,005) | (355) | |||||
| Cash flow | ||||||||
Cash from operating activities | (4,859) | (5,084) | ||||||
CAPEX | (8) | |||||||
Cash from investing activities | (238) | (8) | ||||||
Cash from financing activities | 6,254 | 8,434 | 698 | |||||
FCF | (5,096) | (10,747) | (6,627) | |||||
| Balance | ||||||||
Cash | 6,863 | 4,005 | 440 | |||||
Long term investments | 284 | 20 | ||||||
Excess cash | 6,863 | 4,005 | 460 | |||||
Stockholders' equity | 124 | (1,189) | (4,052) | |||||
Invested Capital | 3,036 | 1,903 | 2,595 | |||||
ROIC | ||||||||
ROCE | 585.56% | |||||||
| EV | ||||||||
Common stock shares outstanding | 4,265 | 202 | 43 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (4,615) | (8,756) | (8,419) | |||||
EV/EBITDA | ||||||||
Interest | 36 | 20 | ||||||
Interest/NOPBT | ||||||||